The Translational Neuroradiology Section (TNS) of the National Institute of Neurological Disorders and Stroke (NINDS) is focused on elucidating the mechanisms by which multiple sclerosis (MS) and related neuroinflammatory pathologies impact the central nervous system (CNS). Given the multifactorial nature of these diseases, high-throughput, high-sensitivity technologies are essential for comprehensive immune profiling and biomarker quantification. The Ella Immunoassay System (Bio-Techne) offers an unparalleled solution for multiplexed, protein-based analysis of serum and plasma samples, with minimal sample volume requirements and superior analytical precision. Specifically, the Ella enables reproducible quantification of biomarkers such as neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), which are critical indicators of axonal damage and astrocyte activation, respectively. Collaborating researchers have consistently cited Ella's rapid turnaround, high sensitivity, and platform stability as key factors supporting its use in translational neuroimmunology studies. Acquisition or continued access to this system is essential to support our ongoing investigations and to maintain the rigor and reproducibility necessary for high-impact CNS researc